Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results

PURPOSE: The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to pathologic myopia. METHODS: This was a prospective, multicenter, consecutive, nonrandomized, interventional case series...

ver descrição completa

Detalhes bibliográficos
Autor principal: Silva, RM (author)
Outros Autores: Ruiz-Moreno, JM (author), Rosa, P (author), Carneiro, A (author), Nascimento, J (author), Rito, LF (author), Cachulo, ML (author), Carvalheira, F (author), Murta, JN (author)
Formato: article
Idioma:eng
Publicado em: 2014
Assuntos:
Inibidores da Angiogénese
Anticorpos Monoclonais
Neovascularização da Coróide
Miopia Degenerativa
Texto completo:http://hdl.handle.net/10400.4/1721
País:Portugal
Oai:oai:rihuc.huc.min-saude.pt:10400.4/1721

Texto Completo

http://hdl.handle.net/10400.4/1721

Registos relacionados